 To demonstrate the reduction of low-density lipoprotein cholesterol LDL-C by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy LMT in comparison with placebo after 24 weeks of treatment in high cardiovascular risk participants with hypercholesterolemia in South Korea and Taiwan. 